Seoul should set new bottom line for USFK: expert
'South Korean officials and experts' current discussions, in dealing with Washington's talks of strategic flexibility of the USFK, are focused on maintaining the current situation or reacting to the US' moves,' Jo Bee-yun, a research fellow at Sejong Institute said in a report.
'However, Seoul must take a proactive approach (toward the issue) and prevent any radical adjustments to the USFK,' she added.
The report comes amid growing speculation that Washington may reduce and reconfigure the USFK to prioritize deterrence of Chinese threats. A May report by the Wall Street Journal indicated that Washington was reviewing wheter to relocate 4,500 troops from South Korea to other areas in the Indo-Pacific region.
US President Donald Trump has been also putting pressure on Seoul to sharply increase its spending on national defense or pay more fo the cost of stationing the USFK on the peninsula.
He recently took a jab at the latest South Korea-US defense cost-sharing deal, dubbed, the Special Measures Agreement, signed under the previous Joe Biden administration last year, saying falsely that the cost was reduced 'to nothing.' The latest SMA for the 2026-2030 period states that Korea is to pay 1.52 trillion won ($1.11 billion) next year, up from 1.4 trillion won this year.
In this regard, Jo pointed out that the gap between the stance on security priorities between Seoul and Washington are growing wider.
'South Korea prioritizes responding to threats from North Korea due to its geopolitical conditions, but the US is attempting to expand the strategic flexibility of the USFK with the focus on deterring threats from China — this has led to a widened gap between stances on security,' she explained.
To prevent further security risks, Jo claimed Seoul must first admit the possibility of a USFK troop reduction and set a new baseline that could help maintain the strength of the South Korea-US alliance and Washington's commitment to extended deterrence.
Specifically, Seoul would need to propose to Washington about maintaining at least 15,000 troops on the peninsula, as well as the current level of the 'Super Squadron' formation test, an initiative by the US Air Force, to consolidate a larger number of F-16 fighter jets into a single squadron at Osan Air Base. The test is aimed enhancing combat effectiveness.
Seoul should also pursue permanent deployment of an F-35A wing, a radar-evading aircraft, to Kunsan Air Base and request Washington to continue to send four-star generals to lead the USFK, she added.
Advancing and developing conventional-nuclear integration options, under which South Korea mobilizes its conventional military assets to back America's nuclear operations in a crisis scenario, would be another key step, Jo noted.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
an hour ago
- Korea Herald
Seoul shares up for 4th day on Samsung gains amid US tariff caution
South Korean stocks finished higher Monday, led by strong gains by tech giant Samsung Electronics amid caution over last-minute negotiations with the United States on its aggressive tariff scheme. The local currency fell against the US dollar. The benchmark Korea Composite Stock Price Index added 13.47 points, or 0.42 percent, to close at 3,209.52, extending its winning streak to a fourth day. Trade volume was heavy at 500.22 million shares worth 13.83 trillion won ($10.01 billion), with losers beating winners 722 to 179. Institutional and foreign investors bought a net 452.01 billion won and 480.78 billion won worth of stocks, respectively, while individuals net sold 998 billion won worth of shares. The index opened higher but moved within a narrow range throughout the session before ending with modest gains, as investors remained cautious ahead of key developments in negotiations between Seoul and Washington over the Donald Trump administration's tariff measures, with just four days remaining until the Aug. 1 deadline. Industry Minister Kim Jung-kwan has departed for Europe to continue trade negotiations with the U.S., while Finance Minister Koo Yun-cheol is scheduled to meet with Treasury Secretary Scott Bessent on Thursday. "With corporate second-quarter earnings being released, now is the time to heighten caution over increased short-term volatility," said Lee Kyung-min, a researcher at Daishin Securities. Market bellwether Samsung Electronics spiked 6.83 percent to 70,400 won on news that it has signed a contract worth over US$16.5 billion won to supply semiconductors to U.S. tech giant Tesla. But chip giant SK hynix lost 1.5 percent to 262,000 won. Major battery maker LG Energy Solution surged 4.68 percent to 380,500 won, and top chemical firm LG Chemical advanced 1.95 percent to 313,000 won. Defense giant Hanwha Aerospace climbed 0.85 percent to 953,000 won. Carmakers gathered ground. Top carmaker Hyundai Motor increased 0.92 percent to 218,500 won, and its sister Kia Motors gained 1.34 percent to 105,500 won. But top financial firm KB Financial dipped 6.99 percent to 110,500 won, and nuclear power plant manufacturer Doosan Enerbility shed 3.64 percent to 63,500 won. Shipbuilders gathered ground on hopes for stronger cooperation with the U.S. Leading shipbuilder HD Hyundai Heavy soared 4.5 percent to 464,500 won, and its rival Hanwha Ocean jumped 8.44 percent to 97,600 won. The local currency was quoted at 1,382 won against the greenback at 3:30 p.m., down 4.1 won from the previous session. (Yonhap)
Korea Herald
2 hours ago
- Korea Herald
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the China National Medical Products Administration (NMPA) has approved XPOVIO ® (selinexor) in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy, a new indication of XPOVIO ®. This approval for XPOVIO ® is based on the data of the BENCH trial, a randomized, controlled, open-label, multicenter Phase III bridging study which compared the safety and efficacy of XVd and Vd regimens in 154 Chinese patients with R/R MM who have received one to three prior lines of therapy. The efficacy and safety data of the BENCH study are generally consistent with those from the global, multicenter, Phase III BOSTON study and met the objectives of the bridging study which showed: Clear superiority of the XVd regimen: compared to the Vd regimen, the XVd regimen demonstrated better clinical efficacy, longer PFS and DOR, a higher ORR, a higher rate of very good partial response (VGPR) or deeper responses and minimal residual disease (MRD) negativity, as well as a trend of prolonged OS. Notable clinical benefits for elderly patients: the study observed particularly notable efficacy in the cohort of elderly patients aged ≥65, validating XPOVIO ® as a better treatment option for this patient population. Prof. Jin Lu, principal investigator of the BENCH study from Peking University People ' s Hospital, said, "MM is the second most common hematologic malignancy. The clinical application of autologous hematopoietic stem cell transplantation (ASCT) and novel agents in the first-line setting have resulted in longer overall survival for patients. However, the condition remains incurable with most patients end up relapsing. As a novel inhibitor of the nuclear export protein that adopts a novel mechanism of action, selinexor was proven by the BENCH study to be significantly efficacious in Chinese patients with MM. This approval for XPOVIO ® is a great news for patients with R/R MM, especially those relapsing for the first time." Prof. Jian Hou, principal investigator of the BENCH study from Shanghai Jiaotong University School of Medicine Affiliated Renji Hospital, commented, "The incidence of MM has been steadily rising year after year. According to the Globocan statistics for 2022, there were 30,300 new cases of MM and 18,662 MM related deaths in China, a figure that highlights an urgent unmet clinical need. Selinexor in combination with bortezomib and dexamethasone incorporates a unique mechanism of action and demonstrated significant efficacy. Moreover, XPOVIO ® does not require intravenous administration, therefore provides clinicians a new treatment strategy that can effectively reduce burden on patients." With a novel mechanism of action, XPOVIO ® is the world's first approved orally-available, selective XPO1 inhibitor, which has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). While bringing XPOVIO ® to more APAC markets, Antengene is also striving to expand the indications of XPOVIO ®. Leveraging the drug's novel mechanism of action, Antengene is currently developing multiple combination regimens of XPOVIO ® for the treatment of various indications including myelofibrosis (MF) and endometrial cancer. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
Korea Herald
2 hours ago
- Korea Herald
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
DAEJEON, South Korea, July 28, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI ® (code name: ALT-L9), a biosimilar referencing Eylea ® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc. EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). "We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added. The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product. About the ALT-L9 Phase 3 study The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA). About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ ( For more information, please visit: Contacts:
